🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Sakar Healthcare Limited SAKAR NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.sakarhealthcare.com

Sakar Healthcare Limited research, develops, manufactures, and sells pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups and injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as anti-infective, analgesic, antihistamine, anthelmintic, anti-malarial, antibacterial, vitamins, antifungal, diuretics, oxytocic, antacid, laxative, anticoagulant, anaesthetic, bronchodilator, adrenergic, sedative, anti-inflammatory, antiemetic, anticonvulsant, antipsychotic, antidepressant, and anti-cancer. The company exports its products to Southeast Asia, Asia, Africa-Anglo and Francophone, MENA countries, and the United States. Sakar Healthcare Limited was incorporated in 2004 and is based in Ahmedabad, India.

READ MORE ›
₹796.50
+151.46% 1Y

Market & Price

Market Cap
₹1,748.31 Cr
Current Price
₹796.50
High / Low (52W)
₹809.00 / ₹312.60
Beta
-

Valuation

Stock P/E
58.14
Industry PE
37.60
Forward P/E
-
PEG Ratio
-
Book Value
₹136.29
Price to Book
5.84
P/S
6.88
EV/EBITDA
25.65
Dividend Yield
-

Profitability & Returns

ROCE
12.82%
ROE
10.00%
ROA
6.64%
Profit Margin
12.00%
Op Margin
28.72%
EPS (Latest Qtr)
₹4.96
EPS (TTM)
₹13.70

Balance Sheet & Liquidity

Debt/Equity
0.17
Quick Ratio
0.46
Current Ratio
1.28
Debt
₹55.30 Cr
Total Assets
₹481.01 Cr
Current Assets
₹140.46 Cr
Working Capital
₹30.92 Cr

Ownership

Promoter Holding
-
Chg in Prom Hold
-
FII / Inst Holding
-
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
₹1,825.38 Cr
Total Revenue (TTM)
₹254.02 Cr
EBITDA
₹71.18 Cr
Free Cash Flow
₹23.52 Cr
Operating Cash Flow
₹49.26 Cr
Shares Outstanding
₹2.19 Cr
Gross Margin
51.47%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
23.59%
Profit 5Y
33.69%
Revenue (YoY)
40.40%
Earnings (YoY)
87.20%

PROS

  • Compounding revenue at 23.6% over 5 years.
  • Profit CAGR of 33.7% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 58.1.

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SAKAR Sakar Healthcare Limited NSEPHARMA 796.50 58.14 ₹1,748.31 Cr - 12.82% 10.00% 23.59% 33.69%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,799.20 37.59 ₹4.32 L Cr 0.92% 17.94% 14.72% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 6,667.00 68.97 ₹1.77 L Cr 0.45% 18.96% 16.19% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,410.80 68.96 ₹1.49 L Cr 0.86% 9.06% 16.98% 13.27% 20.21%
5 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,401.00 29.16 ₹1.13 L Cr 0.93% 14.88% 11.74% 7.23% 11.45%
6 DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA 1,303.50 25.90 ₹1.09 L Cr 0.61% 14.00% 11.83% 10.96% -2.35%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,077.70 21.51 ₹1.08 L Cr 0.09% 19.24% 18.32% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,267.70 19.49 ₹1.04 L Cr 0.53% 28.42% 26.91% 19.10% 131.46%
9 MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA 2,375.60 51.29 ₹98,090.71 Cr 0.08% 13.78% 12.45% 17.73% 14.28%
⚙Ad space

Quarterly Results

Figures in INR.

Metric Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue --50.24 Cr52.74 Cr57.56 Cr70.34 Cr71.10 Cr
Cost of Revenue --14.67 Cr28.95 Cr30.41 Cr35.54 Cr28.38 Cr
Gross Profit --35.57 Cr23.78 Cr27.15 Cr34.81 Cr42.72 Cr
Operating Expenses --25.32 Cr16.65 Cr21.48 Cr22.59 Cr22.42 Cr
Operating Income --10.25 Cr7.13 Cr5.67 Cr12.22 Cr20.30 Cr
EBITDA --15.91 Cr13.10 Cr12.57 Cr19.10 Cr26.41 Cr
Interest Expense --4.19 Cr2.14 Cr1.53 Cr1.78 Cr2.41 Cr
Pretax Income --6.24 Cr5.38 Cr5.36 Cr10.95 Cr18.06 Cr
Tax Provision --47.54 L71.35 L81.81 L70.34 L7.04 Cr
Net Income --5.76 Cr4.67 Cr4.54 Cr10.25 Cr11.02 Cr
Diluted EPS --2.652.112.034.594.96

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue -133.36 Cr153.35 Cr177.58 Cr251.74 Cr
Cost of Revenue -73.79 Cr83.68 Cr82.26 Cr123.28 Cr
Gross Profit -59.57 Cr69.67 Cr95.32 Cr128.46 Cr
Operating Expenses -40.45 Cr48.52 Cr66.52 Cr83.14 Cr
Operating Income -19.12 Cr21.15 Cr28.80 Cr45.32 Cr
EBITDA -37.35 Cr40.70 Cr50.94 Cr71.18 Cr
Interest Expense -5.49 Cr6.75 Cr8.54 Cr7.86 Cr
Pretax Income -16.88 Cr15.90 Cr21.53 Cr39.76 Cr
Tax Provision -4.12 Cr4.23 Cr4.03 Cr9.27 Cr
Net Income -12.76 Cr11.67 Cr17.50 Cr30.48 Cr
Diluted EPS 10.096.865.677.95-

Compounded Sales Growth

5 Years:23.59%
1 Year:40.40%

Compounded Profit Growth

5 Years:33.69%
1 Year:87.20%

Stock Price Performance

1 Year:+151.46%
6 Months:+120.09%
3 Months:+56.25%
1 Month:+27.31%

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets -336.34 Cr388.66 Cr415.26 Cr481.01 Cr
Current Assets -55.92 Cr71.61 Cr88.73 Cr140.46 Cr
Cash & Equivalents -9.33 L25.79 L10.16 L4.22 L
Inventory -15.40 Cr27.73 Cr43.59 Cr70.04 Cr
Receivables -22.08 Cr20.91 Cr30.72 Cr50.08 Cr
Total Liabilities -162.99 Cr126.33 Cr129.79 Cr156.56 Cr
Current Liabilities -54.49 Cr59.06 Cr63.19 Cr109.54 Cr
Long Term Debt -98.23 Cr54.95 Cr53.59 Cr31.35 Cr
Total Debt -119.18 Cr79.35 Cr86.37 Cr55.30 Cr
Total Equity -173.35 Cr262.33 Cr285.48 Cr324.45 Cr
Shares Outstanding 1.71 Cr1.90 Cr2.17 Cr2.19 Cr-

Cash Flows (Annual)

Figures in INR.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -33.34 Cr24.47 Cr34.03 Cr49.26 Cr
Investing Cash Flow --74.38 Cr-51.54 Cr-30.71 Cr-28.35 Cr
Financing Cash Flow -41.10 Cr27.44 Cr-3.48 Cr-20.96 Cr
Capital Expenditure --82.20 Cr-59.56 Cr-32.28 Cr-28.35 Cr
Free Cash Flow --48.85 Cr-35.09 Cr1.75 Cr20.91 Cr
Net Change in Cash -6.34 L37.24 L-15.62 L-4.97 L

Ratios (Annual)

Figures in %.

Metric Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % -44.7%45.4%53.7%51.0%
Operating Margin % -14.3%13.8%16.2%18.0%
Net Margin % -9.6%7.6%9.9%12.1%
ROE % -7.4%4.4%6.1%9.4%
ROCE % -6.8%6.4%8.2%12.2%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SAKAR

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space